

How to cure your patient with minimal damage to their long-term health has been the big challenge in Hodgkin lymphoma since the 1970s, when Andreas Engert was a young boy, watching his father go through treatment at the hands of Mr Hodgkin himself, Volker Diehl. Engert went on to develop a career in this disease, taking over from Diehl as chair of the German Hodgkin Study Group in 2007. In this Cover Story he talks about his high hopes that targeted biologicals may finally provide an alternative to the current toxic regimens on offer. But as he rightly cautions, as more and more innovative drugs are coming into use, and patients in many cancers are living longer, Hodgkin's has a lot to teach about the need to anticipate long-term effects, and to inform and support patients.

What do you think?

- Does the new generation of targeted therapies spell the end of the serious long-term side-effects that are associated with highly toxic multidrug chemotherapy regimens?
- Should we be more cautious about possible long-term effects of the new generation of treatments?

You can read the article [here](#) . Press the comment button at the end and share your views.